Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ben Liu

Showing results (501-510 of 502) with videos related to

Pageof 51
Sort By:
You have reached the last page of results.This site can display upto 502 results.
Frontiers in Pharmacology|March 7, 2022
Hengli<sup>®</sup> Chinese Botulinum Toxin Type A for Treatment of Patients With Overactive Bladder: A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled TrialLimin Liao, Qinggang Liu, Huiling Cong, et al.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2022
Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT)Xinan Sheng, Dingwei Ye, Aiping Zhou, et al.
Pageof 51

Showing results (501-510 of 502) with videos related to

Sort By:
Pageof 51
You have reached the last page of results.This site can display upto 502 results.
Frontiers in Pharmacology|March 7, 2022
Hengli<sup>®</sup> Chinese Botulinum Toxin Type A for Treatment of Patients With Overactive Bladder: A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled TrialLimin Liao, Qinggang Liu, Huiling Cong, et al.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2022
Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT)Xinan Sheng, Dingwei Ye, Aiping Zhou, et al.
Pageof 51